ArticleMolecular & cellular oncology2020
Molecular hallmarks of renal medullary carcinoma: more to c-MYC than meets the eye.
Article in Molecular & cellular oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 19 citations in OpenAlex.
- Differential Efficacy of Bevacizumab and Erlotinib in Preclinical Models of Renal Medullary Carcinoma and Fumarate Hydratase-Deficient Renal Cell Carcinoma.Molecular cancer therapeutics · 2025Article
- Renal cell carcinoma organoids for precision medicine: bridging the gap between models and patients.Journal of translational medicine · 2025Review
- A novel case of glial transdifferentiation in renal medullary carcinoma brain metastasis.Acta neuropathologica communications · 2025Article
- Case Report: Successful delivery following chemotherapy in a pregnant patient with metastatic SMARCB1-deficient renal medullary carcinoma.Frontiers in oncology · 2025Article
- Renal Cell Carcinoma of Variant Histology: New Biologic Understanding Leads to Therapeutic Advances.American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting · 2024Review
- Locoregional Therapies in Immunologically "Cold" Tumors: Opportunities and Clinical Trial Design Considerations.Journal of vascular and interventional radiology : JVIR · 2024Review
- SMARCB1 regulates a TFCP2L1-MYC transcriptional switch promoting renal medullary carcinoma transformation and ferroptosis resistance.Nature communications · 2023Article
- "Adult rhabdoid tumors-a riddle inside an enigma?"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2022Article
- Recent Advances in Renal Medullary Carcinoma.International journal of molecular sciences · 2022Review
- Molecular Characterization of the Tumor Microenvironment in Renal Medullary Carcinoma.Frontiers in oncology · 2022Article
- Efficacy and safety of gemcitabine plus doxorubicin in patients with renal medullary carcinoma.Clinical genitourinary cancer · 2021Article
- Article
- Systemic Therapies for the Management of Non-Clear Cell Renal Cell Carcinoma: What Works, What Doesn't, and What the Future Holds.Clinical genitourinary cancer · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Renal medullary carcinoma (RMC) is a lethal disease that predominantly afflicts young individuals with sickle cell trait. Our recently reported molecular profiling of primary untreated RMC tissues elucidated distinct genomic and immune hallmarks of RMC, and identified MYC-induced replication stress as a targetable vulnerability for this disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.